Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Experimental data have demonstrated favourable effects of statins on endothelial progenitor cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present prospective randomized controlled trial is to determine the effects of aggressive atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ankara University
• Collaborator: Turkish Society of Hematology
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Patients undergoing elective isolated coronary artery bypass surgery with on-pump technique

• Written informed consent

Exclusion Criteria:

• Concomitant valve or aortic surgery

• Left ventricular aneurysm repair

• Re-operation

• Emergency surgery

• History of myocardial infarction within less than 4 weeks

• Hepatic impairment

• Chronic renal impairment

• Drug related side effects (allergy or hypersensitivity)

• Familial Hyperlipidemia

• Autoimmune conditions which require steroids